Atlassian (TEAM) shares climbed roughly 97% over the last 30 days, rising from about $87 to approximately $171. The rally was powered by a blowout fiscal Q4 2026 earnings report released August 6, which triggered a roughly 35% single-day surge — the stock's largest one-day gain in over a decade.

The central question is whether CoreWeave can reclaim $150, a level just below its prior peak of $153.20 and just above the consensus analyst price target near $144. Rapid revenue growth, a $104 billion order backlog, and strong pricing power are the most compelling bullish factors.

Backlog momentum: A contracted revenue backlog that reached roughly $104 billion by mid-2026 provides multi-year visibility into future revenue, anchoring the medium-term growth story. Pricing power: CoreWeave's ability to pass through higher GPU (graphics processing unit) costs via a 25% price increase is viewed by analysts as a potential margin tailwind into 2027.

Capacity execution is the defining catalyst. Nebius is targeting 800 megawatts (MW) to 1 gigawatt (GW) of connected data-center power by the end of 2026, up from roughly 170 MW at the start of the year. A massive contracted backlog underpins visibility. Long-term agreements with Microsoft and Meta, alongside a growing pipeline, support management's $7 billion to $9 billion annualized run-rate revenue (ARR) target for year-end 2026.

AI-driven demand remains the central catalyst. Lumentum's lasers, transceivers, and optical circuit switches are tied to hyperscaler capital spending, which continues to expand faster than the company can add capacity. Supply constraints are a double-edged sword. Persistently tight supply of key lasers supports pricing and margins, but also caps near-term revenue upside.

Nebius Group N.V. (NBIS) is an AI cloud infrastructure ("neocloud") provider trading near $211, with a $300 target representing roughly 42% upside and a key psychological milestone just above its all-time high of $299.86. The strongest bullish factors are explosive revenue growth (454% year over year in the latest quarter), a backlog exceeding $40 billion, and deep backing from NVIDIA (NVDA) , which has disclosed a 9.3% stake.

Investors are debating whether LITE can climb to a $1,200 price target, roughly 44% above its recent trading range near $830. The strongest bullish case rests on surging demand for the lasers and optical components that power artificial intelligence (AI) data centers.

GameStop shares declined roughly 14.8% over the last 30 days, falling from about $21.17 to $18.03 as of the latest session. The primary catalyst was a $1.4 billion debt-for-equity swap announced in early August, which sparked a sharp single-day selloff on dilution concerns.

Target in focus: $300, roughly 10% above Johnson & Johnson's recent price near $273 and matching the most bullish Wall Street price target. Bullish case: Accelerating growth in Innovative Medicine, a maturing MedTech pipeline, and a prolonged rally that has lifted shares sharply off their 52-week low.

Genie Energy Ltd. (NYSE: GNE ) recently traded near $15.30, making a $20 stock price target roughly 31% above current levels. The company carries a fortress-like balance sheet, with net cash of roughly $200 million — close to half its market capitalization — plus ongoing share buybacks and a dividend.

Bit Digital, Inc. (NASDAQ: BTBT) trades near $1.37, and the lowest Wall Street analyst price target of $3.50 implies roughly 156% upside from current levels. The company is undergoing a strategic transformation — pivoting away from Bitcoin mining toward Ethereum (ETH) treasury and staking, as well as high-performance computing (HPC) and AI cloud services.

IonQ, Inc. ( IONQ ) trades near $41, making a move to $50 roughly a 22% advance — a realistic but not guaranteed objective. $50 is a widely discussed level: J.P. Morgan holds a $50 target, Morgan Stanley sits at $49, and several analysts describe $50 as a key entry point.

Bloom Energy (BE) trades near $204 after pulling back from a 52-week high of $351.28, making a return to the psychologically significant $300 level a realistic, widely discussed objective. The strongest bullish case rests on surging demand for on-site power from AI data centers, triple-digit revenue growth, and a backlog measured in the tens of billions of dollars.

The selected price target is $1.00 — a psychological round number that RITR traded above as recently as late 2025, before a sharp multi-month decline. The stock has collapsed roughly 98% from its 2024 IPO price and now trades near $0.11, making a return to $1 an increase of roughly 800% from current levels.

The most widely cited public price objective for Autonomix Medical, Inc. (NASDAQ: AMIX) is the $42 analyst price target issued by Maxim Group, a level that would require a roughly seven-fold move from recent prices. AMIX is a development-stage medical device company with no reported revenue, a shrinking cash balance, and a history of dilutive capital raises.

The selected target: $8 per share, a psychological round number sitting just below ACDC's 52-week high of $8.22. Current position: ProFrac Holding Corp. (ACDC) trades near $4.82, meaning reaching $8 would require a gain of roughly 65% from recent levels.

Selected target: $500 per share, a round-number milestone that sits roughly one-third above recent prices near $375. Bullish case: The da Vinci 5 upgrade cycle, strong international procedure growth, and a consensus analyst rating of Buy support the upside narrative.

Canaan Inc. (CAN) shares gained roughly 50% over the last 30 days, rebounding from about $0.24 to around $0.35 after touching a 52-week low of $0.1516 in early August. The rally was supported by a Nasdaq listing-compliance extension, a share-repurchase program funded by its digital-asset treasury, and insider stock purchases by executives.

INO shares are up +7.63% intraday, trading near $1.27 versus a $1.18 prior close, during regular market hours. The primary catalyst is a newly announced collaboration with Akeso, Dana-Farber Cancer Institute, and Mass General Brigham to evaluate Akeso's cadonilimab combined with Inovio's DNA medicine INO-5412 in glioblastoma.

ASST is up roughly +11.20% during regular market hours, rising from Friday's $18.22 close to about $20.26. The rally is tied to its Bitcoin-treasury strategy, with Strive announcing the purchase of an additional 1,110 BTC (~$81.5M).